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Objective: To investigate the association between the cluster of differentiation 14
(CD14)-159C/T (rs2569190) gene polymorphism and susceptibility to acute brucellosis
in an Iranian population.
Methods: The study included 153 Iranian patients with active brucellosis and 128
healthy individuals as the control group. Genotyping of the CD14 variant was performed
using an ampliﬁcation refractory mutation system-polymerase chain reaction method.
Results: The prevalence of CD14-159 TT and CT genotypes were associated with
increased risk of brucellosis [odds ratio (OR) = 1.993, 95% conﬁdence interval (95%
CI) = 1.07–3.71, P = 0.03 for CT; OR = 3.869, 95% CI = 1.91–7.84, P = 0.01 for TT
genotype. Additionally, the minor allele (T) was signiﬁcantly more frequently present in
brucellosis patients than in controls (61% vs. 45%, respectively), and was a risk factor for
brucellosis (OR = 3.058, 95% CI = 1.507–6.315, P = 0.01).
Conclusions: The ﬁndings provided suggestive evidence of association of the CD14-
159C/T gene polymorphism with susceptibility to acute brucellosis in the Iranian
population.1. Introduction
Brucellosis (or Malta fever, Gibraltar fever, Cyprus fever,
Danube fever, undulant fever, Mediterranean fever and Bang's
disease) is one of the most frequent zoonotic infections world-
wide, transmitted to humans by eating contaminated, unpas-
teurized dairy products, direct contact with infected animal, and
through the inhalation of infected aerosolized particles [1–4]. The
majority of cases arise in the Mediterranean countries of Europe
and Africa, Mexico, and Central and South America, India,
Central Asia and Middle East including Iran [4].
Brucella spp. (pleomorphic, gram-negative, non-spore-
forming coccobacillus bacteria) causes severe debilitating anddisabling disease that is accompanied with manifestations such
as fever, weakness, sweating, weight loss, headache, persisted
joint pain, neurological complications, endocarditis and testic-
ular or bone abscess formation [1,2,4,5]. Brucella spp. are
facultative intracellular bacteria that have the ability to evade
from killing mechanism of immune system and multiply
within in organs with frequent macrophages such as liver,
spleen, lung, bone marrow and synovium (reticuloendothelial
system) [4,6]. Among all species of Brucella genus, three
species including Brucella melitensis, Brucella abortus, and
Brucella suis are the most commonly associated with human
disease [7].
Cluster of differentiation 14 (CD14) is a glycosyl-
phosphatidylinositol-anchored molecule that is mainly
expressed on cell membrane surfaces of monocyte/macrophage
lineage [8,9], and acts as a pattern recognition receptor in innate
immunity for detection of variety of ligands such as bacterial
products, microbial cell wall components and even whole
bacteria. Particularly, CD14 is the speciﬁc receptor for the
lipopolysaccharide (LPS) of gram-negative bacteria [10,11].nder the CC BY-NC-ND license
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negative bacteria and is called ‘bacterial endotoxin’ [12]. LPS
is the main virulence factor of Brucella and has a role in cell
entry and immune evasion of the infected cell [6]. LPS also
has an ability to induce the production of interleukin (IL)-12
resulting in promotion of T helper (Th) 1 responses and
inhibition of Th-2 responses in the host [13]. CD14 as a co-
receptor for the toll-like receptor (TLR) and together with
TLR4 forms a complex that activates the innate immune system
and starts a variety of effector functions including secretion of
pro-inﬂammatory cytokines such as IL-1, IL-6, tumor necrosis
factor-a, nitric oxide, oxygen radicals and complement compo-
nents as well as cell proliferation, subsequent binding to LPS
[8,13–15]. Nevertheless, high production of these molecules may
cause intense harmful consequences including severe
inﬂammatory responses, septic shock and death [15]. Moreover,
a soluble type of CD14 (sCD14) is produced by monocytes,
hepatocytes and endothelial cells and is present in the
circulation and other body ﬂuids. sCD14 is derived both from
secretion of CD14 and from enzymatically cleaved glycosyl-
phosphatidylinositol-anchored membrane type of CD14 [10,16].
Since sCD14 plasma levels increases during inﬂammation and
infection, it is believed that sCD14 is an acute-phase protein,
which is increased in several inﬂammatory processes [8,15,17].
The human CD14 gene is located on chromosome 5q31.1
[14]. Several single nucleotide polymorphisms (SNPs), including
-2451G/C (rs2569192), -1855A/G (rs3138076), -1619A/G
(rs2915863) and -159C/T (rs2569190), have been identiﬁed in
promoter region of the CD14 gene [18,19]. One of the most
extensively studied SNPs, the -159C/T (rs2569190), includes a
substitution of C / T resulting in elevated transcriptional
activity and expression levels of CD14 [14,20].
Thus far, the CD14-159C/T gene polymorphism has been
examined in several inﬂammatory and infectious diseasesTable 1
Clinical characteristics of brucellosis patients.
Number Percent (%)
Fever 99 64.70
Myalgia 38 24.83
Anorexia 85 55.55
Headache 58 37.90
Malaise 70 45.75
Low back pain 35 22.87
Fatigue 65 42.48
Sweating 93 60.78
Weight loss 53 34.64
Arthralgia 84 54.90
Paresthesia 29 18.95
Palpitations 26 16.99
Nausea 23 15.03
Rash 18 11.76
Dysuria 17 11.11
Blood culture (positive) 105 68.62
Brucella spp.:
Brucella melitensis 114 74.17
Brucella abortus 38 25.83
Clinical complications:
Arthritis 22 14.37
Endocarditis 2 1.30
Spondylitis 4 2.61
Neurobrucellosis 7 4.57
Meningitis 1 0.65
Mortality 6 3.92including tuberculosis [8,9,21], brucellosis [22], Chlamydia
pneumoniae infection [23,24], Helicobacter pylori infection [25],
hepatitis B and C [26,27] and severe acute respiratory syndrome
[28], but the results have been inconsistent and conﬂicting.
Therefore, the current study aimed to evaluate the possible
association between the CD14-159C/T (rs2569190) gene
polymorphism and susceptibility to acute brucellosis in an
Iranian population.
2. Materials and methods
2.1. Study population
The current case-control retrospective study included 153
patients (102 men and 51 women) suffering from active
brucellosis, age range 6–76 years old and
mean ± SD = 31.24 ± 16.6 and 128 healthy individuals as the
control group (93 men and 35 women), age range 19–64 years
and mean ± SD = 34.04 ± 13.69. Blood sample from each
participant was collected in EDTA-containing tubes for DNA
isolation after taking an informed consent from all patients and
healthy individuals. All patients were either milk farmers
(including diagnosed infected animals) or had a history of
consuming raw milk and unpasteurized dairy products. De-
mographic characteristics of patients and their clinical compli-
cations are shown in Table 1. Brucellosis was diagnosed
according to the clinical manifestations (including fever, night
sweating, weakness, malaise, weight loss, splenomegaly, lym-
phadenophathy, myalgia and arthralgia) and positive blood
cultures as described previously [29–32]. The control group
included healthy blood donors with no evidence of brucellosis
and genetic disorders and matched for age, sex, and
geographic area. The control subjects had the same
background as patients and were at the same risk of exposure
for brucellosis.
2.2. Culture and identiﬁcation of organism
Brucella spp. were cultivated on 5% sheep blood-agar plates
and incubated at 37 C in the contact to 5%–10% of CO2 con-
ditions for 48 h. A typical and well-isolated Brucella like colony
is tiny, transparent, raised, and convex, with an entire edge and
smooth and glistening surface along the streak lines by exam-
ining macroscopically by Gram's stain [33]. Serological tests,
deﬁned as wright titre 1/160 plus mercaptoethanol test 1/
80 or coomb's wright 1/320 certiﬁed the brucellosis
infection. The complete details of the organism identiﬁcation
methods have been described previously in papers by this
research team [29–32].
2.3. Genotyping of CD14-159C/T (rs2569190) SNP
Genomic DNA was extracted from the peripheral blood
leukocytes by the ‘salting-out’ method as explained previously
[34]. The quality of the isolated DNA was checked by
electrophoresis on 1% agarose gel, quantitated
spectrophotometrically and stored at −20 C still further use.
The CD14-159C/T SNP, rs2569190, was genotyped using an
ampliﬁcation refractory mutation system-polymerase chain re-
action method as described previously by Karhukorpi et al
[25,35]. This allele-speciﬁc, single-tube polymerase chain reaction
Mehdi Moghadampour et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(3): 247–251 249method uses four primers including two allele speciﬁc primers
(cfors for the C allele and trevs for the T allele) and two outer
primers (cdp1 and cdp2) for the control band. An additional
mismatch was inserted at the penultimate 30 nucleotide (under-
lined) of the allele-speciﬁc primers to increase the speciﬁcity of
the PCR reaction. The primer sequences were as follows: cfors:
50-CTC CAG AAT CCT TCC TGT TAC GAC-30, trevs: 50-TGT
AGG ATG TTT CAG GGA GGG GTA-30, cdp1: 50-TTG GTG
CCA ACA GAT GAG GTT CAC-30, cdp2: 50-TTC TTT CCT
ACA CAG CGG CAC CC-30. The PCR conditions for the
CD14-159C/T (rs2569190) polymorphism were as followed: an
initial denaturation at 95 C for 5 min; 30 cycles at 95 C for
30 s, 60 C for 30 s and 72 C for 1 min; the ﬁnal extension step
proceeded at 72 C for 5 min [25,35]. The PCR products were
separated by standard electrophoresis on 2% agarose gel
containing ethidium bromide. The PCR products included a
381 bp band for the T allele, a 227 bp band for the C allele
and a 561 bp band for the control.
2.4. Statistical analysis
All statistical analyses were performed applying the SPSS
software for Windows, version 18.0 (SPSS Inc, Chicago IL,
USA). The association among genotypes and brucellosis was
calculated by reckoning the odds ratio (OR) and 95% conﬁdence
interval (95% CI) from logistic regression analyses. P values
below 0.05 were considered statistically signiﬁcant. The Hardy–
Weinberg equilibrium was tested with the c2 test for the SNP
under consideration.
3. Results
The CD14 polymorphism, -159C/T, was successfully geno-
typed in 153 brucellosis patients and 128 control subjects. No
deviation from Hardy–Weinberg equilibrium was observed in
the studied case and control groups (P > 0.05). The genotype
and allele frequency of the SNP in the studied groups were
shown in Table 2.
The results showed that the CD14 polymorphism, -159C/T,
was associated with the risk of brucellosis in our population. At
genotypic level, the CD14 CT, and TT genotypes were more
frequent in the patients group compared to cases, and were
associated with increased risk of brucellosis in the codominant
model (OR = 1.993, 95% CI = 1.07–3.71, P = 0.03 for CT;
OR = 3.869, 95% CI = 1.91–7.84, P = 0.01 for TT genotype).
Additionally, the CT + TT vs. CC genotype in the dominant
model was a risk factor for brucellosis (OR = 2.514, 95%Table 2
The genotype and allele frequencies of CD14-159C/T SNP between brucello
SNPs Allele/genotype Brucellosis patients
Number Percent (%)
CD14-159C/T Models
Codominant CC 22 14.4
CT 75 49.0
TT 56 36.6
Dominant CC 22 14.4
CT + TT 131 85.6
Recessive CC + CT 97 63.4
TT 56 36.6
Alleles C 119 38.8
T 187 61.2CI = 1.34–4.73, P = 0.02). Likewise, in the recessive model, the
TT genotype vs. CC + CT was associated with the risk of
brucellosis (OR = 2.379, 95% CI = 1.33–4.27, P = 0.02). At
allelic level, the minor allele (T) was signiﬁcantly more
frequently present in brucellosis patients than in controls (61%
vs. 45%, respectively), and was a risk factor for brucellosis
(OR = 3.058, 95% CI = 1.507–6.315, P = 0.01).
4. Discussion
Our study provided data on the association between one
important SNP in the 50 ﬂanking region of the CD14 gene and
acute brucellosis using genotype analysis. The results showed
that the prevalence of −159 homozygote TT genotype as well as
T allele were much higher in brucellosis patients than in controls
(36.6% vs. 19.5% and 61% vs. 44%, respectively). The carriers
of the TT genotype and T allele were at 3.8-fold or 3-fold higher
risk of brucellosis, respectively, than those with the CC geno-
type or C allele.
Several studies have been conducted to show the impact of
the CD14-159C/T SNP on the risk of infectious diseases [9,18,21–
23]. To the best of our knowledge, there is only one study
assessing the association of CD14, -159C/T polymorphism
and brucellosis [22]. Haidari et al [22], in their study on
brucellosis in a Western Iranian population have shown that
the frequency of the TT genotype was higher in the patients
than in controls (34.5% vs. 15.5%). They suggested that the
homozygousity for T allele of promoter of CD14 gene may
confer an increased risk of brucellosis, which supports our
ﬁndings. Moreover, our results regarding CD14-159C/T
polymorphism are in agreement with several infectious studies
on pulmonary tuberculosis [9,18,21] and C. pneumoniae
infection [23]. In contrast, other studies reported no association
between CD14-159C/T SNP and Chlamydia trachomatis
infection [36], Campylobacter jejuni infection [37] and severe
acute respiratory syndrome [28].
Most Brucella species are highly virulent causing an acute
infection in their hosts. The LPS of this bacterium is one of the
essential components for the ﬁrst steps in the establishment of
an intracellular replication niche, in which Brucella survives
and multiplies [7]. LPS is a potent stimulator of monocytes and
macrophages [25]. Activation of macrophages is one of the
early events in the innate immunity to intracellular
pathogens. CD14 is a high-afﬁnity receptor for bacterial LPS
and is expressed mainly by cells of monocyte/macrophage
lineage. The binding of LPS to CD14 results in cellular acti-
vation and initiates a range of effector functions includingsis patients and controls.
Controls OR (95% CI) P value
Number Percent (%)
38 29.7 Ref. –
65 50.8 1.993 (1.07–3.71) 0.03
25 19.5 3.869 (1.91–7.84) 0.01
38 29.7 Ref. –
90 70.3 2.514 (1.34–4.73) 0.02
103 29.7 Ref. –
25 19.5 2.379 (1.33–4.27) 0.02
143 55.4 Ref. –
115 44.6 3.058 (1.507–6.315) 0.01
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receptor for the TLR is transferring LPS to the TLR4/MD-2
signaling complex. Engagement of this complex results in the
activation of innate immunity mechanisms such as the release
of proinﬂammatory cytokines and subsequently severe in-
ﬂammatory responses as well as in worse circumstances of
septic shock and death [15,19]. Some studies have been
performed to explain the impact of the CD14-159C/T SNP
on CD14 protein expression [8,38]. The CD14-159C/T
polymorphism is located at a GC box close to the
transcription start site, which serves as a binding site for
Sp1-Sp2/Sp3 transcription factors that are involved in the
regulation of CD14 gene transcription [15]. The T variant of this
SNP is associated with high expression of CD14 on the surface
of monocytes and macrophages, which further increases the
inﬂammatory response [39,40]. Thus, this SNP could be a
genetic factor for inter-individual differences in susceptibility
to infectious diseases like brucellosis. Our results highlight the
role of CD14 in the inﬂammatory response and the effect of its
promoter polymorphism on the host immune defense.
In conclusion, our study provided evidence that the CD14-
159, CT and TT genotypes may serve as risk factors for
brucellosis infection in our population. Further studies on larger
populations with different ethnicities are required to validate our
ﬁndings. More inclusive understanding of the basic mechanisms
underlying infections pathogenesis may lead to the development
and application of efﬁcient products for the treatment of
brucellosis.
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